|
94
|
324
|
5gtzA |
Crystal structure of egfr 696-1022 t790m in complex with jts-1-39 |
|
95
|
312
|
5h3qA |
Crystal structure of trka kinase with ligand |
|
83
|
289
|
5gnkA |
Crystal structure of egfr 696-988 t790m in complex with lxx-6-34 |
|
81
|
315
|
5gtyA |
Crystal structure of egfr 696-1022 t790m in complex with lxx-6-26 |
|
99
|
309
|
5ftqA |
Crystal structure of the alk kinase domain in complex with cmpd 17 |
|
92
|
321
|
5fedA |
Egfr kinase domain in complex with a covalent aminobenzimidazole inhibitor. |
|
89
|
322
|
5feeA |
Egfr kinase domain t790m mutant in complex with a covalent aminobenzimidazole inhibitor. |
|
83
|
306
|
5fdxA |
Structure of ddr1 receptor tyrosine kinase in complex with d2164 inhibitor at 2.65 angstroms resolution. |
|
97
|
309
|
5ftoA |
Crystal structure of the alk kinase domain in complex with entrectinib |
|
75
|
302
|
5fm2A |
Crystal structure of hyper-phosphorylated ret kinase domain with (proximal) juxtamembrane segment |
|
95
|
293
|
5eycA |
Crystal structure of c-met in complex with naphthyridinone inhibitor 5 |
|
71
|
305
|
5fm3A |
Crystal structure of hyper-phosphorylated ret kinase domain with (proximal) juxtamembrane segment |
|
89
|
303
|
5flfA |
Disease linked mutation in fgfr |
|
85
|
321
|
5feqA |
Egfr kinase domain in complex with a covalent aminobenzimidazole |
|
94
|
290
|
5ek7A |
Structure of the autoinhibited epha2 jms-kd |
|
87
|
324
|
5em7A |
Egfr kinase domain mutant "tmlr" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
90
|
322
|
5edpA |
Egfr kinase (t790m/l858r) apo |
|
91
|
298
|
5ew3A |
Human vascular endothelial growth factor receptor 2 (kdr) kinase domain in complex with aal993 |
|
93
|
323
|
5em6A |
Egfr kinase domain mutant "tmlr" with pyridone compound 19: 4-[(2-azanylpyrimidin-4-yl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
86
|
322
|
5edqA |
Egfr kinase (t790m/l858r) with inhibitor compound 15: ~{n}-(7-chloranyl-1~{h}-indazol-3-yl)-7,7-dimethyl-2-(1~{h}-pyrazol-4-yl)-5~{h}-furo[3,4-d]pyrimidin-4-amine |
|
92
|
302
|
5ew8A |
Fibroblast growth factor receptor 1 in complex with jnj-4275693 |
|
93
|
309
|
4zseA |
Crystal structure of egfr 696-1022 t790m/v948r, crystal form ii |
|
92
|
309
|
5eg3A |
Crystal structure of the activated fgf receptor 2 (fgfr2) kinase domain in complex with the csh2 domain of phospholipase c gamma (plcgamma) |
|
88
|
301
|
5e1sA |
The crystal structure of insr tyrosine kinase in complex with the inhibitor bi 885578 |
|
97
|
291
|
5eobA |
Crystal structure of cmet in complex with novel inhibitor |
|
88
|
323
|
5em5A |
Egfr kinase domain mutant "tmlr" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
93
|
322
|
5edrA |
Egfr kinase (t790m/l858r) with inhibitor compound 27: ~{n}-(1~{h}-indazol-3-yl)-7,7-dimethyl-2-(2-methylpyrazol-3-yl)-5~{h}-furo[3,4-d]pyrimidin-4-amine |
|
92
|
297
|
5eydA |
Crystal structure of c-met in complex with amg 337 |
|
90
|
323
|
5em8A |
Egfr kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{n}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{h}-pyridine-3-carboxamide |
|
40
|
246
|
5aoqA |
Structural basis of neurohormone perception by the receptor tyrosine kinase torso |
|
88
|
297
|
5amnA |
The discovery of 2-substituted phenol quinazolines as potent and selective ret kinase inhibitors |
|
85
|
309
|
5am6A |
Native fgfr1 with an inhibitor |
|
92
|
317
|
5d41A |
Egfr kinase domain in complex with mutant selective allosteric inhibitor |
|
90
|
307
|
5am7A |
Fgfr1 mutant with an inhibitor |
|
88
|
297
|
5dg5A |
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in complex with altiratinib analog dp-4157 |
|
86
|
294
|
4ypsA |
(r)-2-phenylpyrrolidine substitute imidazopyridazines: a new class of potent and selective pan-trk inhibitors |
|
92
|
323
|
5czhA |
Egfr l858r mutant in complex with an optimal peptide substrate |
|
81
|
297
|
4yneA |
(r)-2-phenylpyrrolidine substitute imidazopyridazines: a new class of potent and selective pan-trk inhibitors |
|
120
|
583
|
5cusA |
Crystal structure of serbb3-fab3379 complex |
|
99
|
323
|
5cziA |
Egfr l858r mutant in complex with a shc peptide substrate |
|
94
|
316
|
5cnoA |
Crystal structure of the egfr kinase domain mutant v924r |
|
93
|
316
|
5cnnA |
Crystal structure of the egfr kinase domain mutant i682q |
|
87
|
291
|
4xcuA |
Crystal structure of fgfr4 with an irreversible inhibitor |
|
93
|
295
|
4xyfA |
Crystal structure of c-met in complex with (s)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole |
|
77
|
305
|
4xstE |
Structure of the endoglycosidase-h treated l1-cr domains of the human insulin receptor in complex with residues 697-719 of the human insulin receptor (a-isoform) |
|
94
|
310
|
4xlvA |
Crystal structure of the activated insulin receptor tyrosine kinase dimer |
|
92
|
295
|
4xmoA |
Crystal structure of c-met in complex with (r)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-3-methylisoxazole |
|
2
|
12
|
4xssF |
Insulin-like growth factor i in complex with site 1 of a hybrid insulin receptor / type 1 insulin-like growth factor receptor |
|
78
|
309
|
4xssE |
Insulin-like growth factor i in complex with site 1 of a hybrid insulin receptor / type 1 insulin-like growth factor receptor |
|
5
|
16
|
4xstF |
Structure of the endoglycosidase-h treated l1-cr domains of the human insulin receptor in complex with residues 697-719 of the human insulin receptor (a-isoform) |
